Memorial Sloan Kettering Cancer Center

Sorting 31 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
  • CELMoD
  • Phase 1/2
  • Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Not currently accepting

MonumenTAL-8

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
  • Bispecific Antibody
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 2

Accepting patients

Stopping Maintenance Therapy

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
  • Maintenance

Accepting patients

NUTRIVENTION-4

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 2
  • Has results

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

CAR T Post Hematopoietic Cell Transplant

A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

Belantamab Mafodotin Combination Therapy

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1/2

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3
5 hidden based on your filters. Show All